1 Introduction Acute myeloid leukemia (AML) is a biologically heterogeneous malignancy characterized by clonal expansion of myeloid progenitor cells derived from a multipotent stem cell [1-4]. Regarding ontogeny, AML can develop either de novo or from antecedent myelodysplastic neoplasms (MDS) or myeloproliferative neoplasms [5, 6]. AML represents the most common form of acute leukemia in adults, and its incidence rises with age, with a median age of diagnosis at 68 years (SEER data 2025).